Very recently, a vector targeting PSMA, [64Cu]Cu-DOTAH2-PSMA, was evaluated for theranostic applications in mice bearing LNCaP prostate tumours, with very promising results for both imaging [11] and therapy [12]. This evidence concerns the gene FOLH1 and prostate neoplasm.